Supportive Care in Cancer

, Volume 24, Issue 10, pp 4081–4082 | Cite as

Response to RE: Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up

  • Cari Lewis
  • Pengcheng Xun
  • Ka HeEmail author
Letter to the editor

Dear Editor,

We appreciate the opportunity to address the comments and concerns of van Erning et al. about our study [1].

As van Erning et al. point out, stage II colon cancer patients are considered for adjuvant chemotherapy mainly in the presence of high-risk prognostic features, such as a T4 lesion, inadequate lymph node sampling, vascular invasion, obstruction or perforation, or a poorly differentiated/undifferentiated histology [2]. These prognostic factors are likely to influence the outcomes such as recurrence and mortality. The primary purpose of our study was to investigate lifestyle changes after diagnosis in relation to quality of life and chemotherapy was used as a surrogate of prognostic features. Thus, detailed information on prognostic factors related to chemotherapy was not recorded during the data collection phase. Although we mentioned that unknown or insufficient information may confound our results, this limitation should be emphasized in the discussion.



Cancer Survivor American Cancer Society Colon Cancer Patient Enrollment Rate Prognostic Feature 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest. Authors have full control of the primary data and agree to allow the Journal of Supportive Care in Cancer to review if requested.


  1. 1.
    Lewis CM, Xun P, He K (2016) Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up. Support Care Cancer 24(4):1656–1661Google Scholar
  2. 2.
    Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419CrossRefPubMedGoogle Scholar
  3. 3.
    Satia JA, Campbell MK, Galanko JA, James A, Carr C, Sandler RS (2004) Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. Cancer Epidemiol Biomark Prev 13(6):1022–1031Google Scholar
  4. 4.
    Blanchard CM, Denniston MM, Baker F, Ainsworth SR, Courneya KS, Hann DM, et al. (2003) Do adults change their lifestyle behaviors after a cancer diagnosis? Am J Health Behav 27(3):246–256CrossRefPubMedGoogle Scholar
  5. 5.
    Maskarinec G, Murphy S, Shumay D, Kakai H (2001) Dietary changes among cancer survivors. Eur J Cancer Care 10(1):12–20CrossRefGoogle Scholar
  6. 6.
    Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, et al. (2003) Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361(9368):1496–1501CrossRefPubMedGoogle Scholar
  7. 7.
    Hawkins NA, Smith T, Zhao L, Rodriguez J, Berkowitz Z, Stein KD (2010) Health-related behavior change after cancer: results of the American Cancer Society’s studies of cancer survivors (SCS). J Cancer Surviv 4(1):20–32CrossRefPubMedGoogle Scholar
  8. 8.
    Verhoeff S, van Erning F, Lemmens V, de Wilt J, Pruijt J (2016) Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer 139(1):187–193CrossRefPubMedGoogle Scholar
  9. 9.
    Lindskog EB, Gunnarsdóttir KÁ, Derwinger K, Wettergren Y, Glimelius B, Kodeda K (2014) A population-based cohort study on adherence to practice guidelines for adjuvant chemotherapy in colorectal cancer. BMC Cancer 14:948. doi:  10.1186/1471-2407-14-948
  10. 10.
    Kneuertz PJ, Chang GJ, Hu C-Y, Rodriguez-Bigas MA, Eng C, Vilar E, et al. (2015) Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg 150(5):402–409CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of Epidemiology and Biostatistics, School of Public Health - BloomingtonIndiana UniversityBloomingtonUSA

Personalised recommendations